Literature DB >> 31973644

Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid.

Angela M Boutté1, Vivian Hook2, Bharani Thangavelu1, George Anis Sarkis3,4, Brittany N Abbatiello1, Gregory Hook5, J Steven Jacobsen5, Claudia S Robertson6, Janice Gilsdorf1, Zhihui Yang3, Kevin K W Wang3, Deborah A Shear1.   

Abstract

Cathepsin B (CatB), a lysosomal cysteine protease, is important to brain function and may have dual utility as a peripheral biomarker of moderate-severe traumatic brain injury (TBI). The present study determined levels of pro- and mature (mat) CatB protein as well as cysteine protease activity within the frontal cortex (FC; proximal injury site), hippocampus (HC; distal injury site), and cerebral spinal fluid (CSF) collected 1-7 days after craniotomy and penetrating ballistic-like brain injury (PBBI) in rats. Values were compared with naïve controls. Further, the utility of CatB protein as a translational biomarker was determined in CSF derived from patients with severe TBI. Craniotomy increased matCatB levels in the FC and HC, and led to elevation of HC activity at day 7. PBBI caused an even greater elevation in matCatB within the FC and HC within 3-7 days. After PBBI, cysteine protease activity peaked at 3 days in the FC and was elevated at 1 day and 7 days, but not 3 days, in the HC. In rat CSF, proCatB, matCatB, and cysteine protease activity peaked at 3 days after craniotomy and PBBI. Addition of CA-074, a CatB-specific inhibitor, confirmed that protease activity was due to active matCatB in rat brain tissues and CSF at all time-points. In patients, CatB protein was detectable from 6 h through 10 days after TBI. Notably, CatB levels were significantly higher in CSF collected within 3 days after TBI compared with non-TBI controls. Collectively, this work indicates that CatB and its cysteine protease activity may serve as collective molecular signatures of TBI progression that differentially vary within both proximal and distal brain regions. CatB and its protease activity may have utility as a surrogate, translational biomarker of acute-subacute TBI.

Entities:  

Keywords:  biomarkers; cathepsin B; clinical TBI; cysteine protease; head trauma; penetrating ballistic-like brain injury; translational rodent models; traumatic brain injury

Mesh:

Substances:

Year:  2020        PMID: 31973644      PMCID: PMC7307674          DOI: 10.1089/neu.2019.6537

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  63 in total

1.  Cathepsin B-indicator for the release of lysosomal cysteine proteinases in severe trauma and inflammation.

Authors:  I Assfalg-Machleidt; M Jochum; D Nast-Kolb; M Siebeck; A Billing; T Joka; G Rothe; G Valet; R Zauner; H P Scheuber
Journal:  Biol Chem Hoppe Seyler       Date:  1990-05

2.  Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers.

Authors:  Richard Rubenstein; Binggong Chang; John K Yue; Allen Chiu; Ethan A Winkler; Ava M Puccio; Ramon Diaz-Arrastia; Esther L Yuh; Pratik Mukherjee; Alex B Valadka; Wayne A Gordon; David O Okonkwo; Peter Davies; Sanjeev Agarwal; Fan Lin; George Sarkis; Hamad Yadikar; Zhihui Yang; Geoffrey T Manley; Kevin K W Wang; Shelly R Cooper; Kristen Dams-O'Connor; Allison J Borrasso; Tomoo Inoue; Andrew I R Maas; David K Menon; David M Schnyer; Mary J Vassar
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

3.  Microglial secreted cathepsin B induces neuronal apoptosis.

Authors:  P J Kingham; J M Pocock
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

4.  Neuronal loss and brain atrophy in mice lacking cathepsins B and L.

Authors:  Ute Felbor; Benedikt Kessler; Walther Mothes; Hans H Goebel; Hidde L Ploegh; Roderick T Bronson; Bjorn R Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

5.  Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats.

Authors:  Xian-Jian Huang; Olena Glushakova; Stefania Mondello; Ken Van; Ronald L Hayes; Bruce G Lyeth
Journal:  J Neurotrauma       Date:  2015-05-14       Impact factor: 5.269

6.  Microglial cathepsin B: an immunological examination of cellular and secreted species.

Authors:  R E Ryan; B F Sloane; M Sameni; P L Wood
Journal:  J Neurochem       Date:  1995-09       Impact factor: 5.372

7.  Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease.

Authors:  Binggui Sun; Yungui Zhou; Brian Halabisky; Iris Lo; Seo-Hyun Cho; Sarah Mueller-Steiner; Nino Devidze; Xin Wang; Anders Grubb; Li Gan
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

8.  Correlations between blood-brain barrier disruption and neuroinflammation in an experimental model of penetrating ballistic-like brain injury.

Authors:  Tracy L Cunningham; Casandra M Cartagena; Xi-Chun M Lu; Melissa Konopko; Jitendra R Dave; Frank C Tortella; Deborah A Shear
Journal:  J Neurotrauma       Date:  2014-03-01       Impact factor: 5.269

9.  Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.

Authors:  Jessica Gill; Lawrence Latour; Ramon Diaz-Arrastia; Vida Motamedi; Christine Turtzo; Pashtun Shahim; Stefania Mondello; Christina DeVoto; Eliseo Veras; David Hanlon; Linan Song; Andreas Jeromin
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

10.  The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion.

Authors:  Starlee Lively; Lyanne C Schlichter
Journal:  J Neuroinflammation       Date:  2013-06-21       Impact factor: 8.322

View more
  7 in total

1.  Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions.

Authors:  Michael C Yoon; Angelo Solania; Zhenze Jiang; Mitchell P Christy; Sonia Podvin; Charles Mosier; Christopher B Lietz; Gen Ito; William H Gerwick; Dennis W Wolan; Gregory Hook; Anthony J O'Donoghue; Vivian Hook
Journal:  ACS Chem Biol       Date:  2021-08-20       Impact factor: 4.634

Review 2.  Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders.

Authors:  Gregory Hook; Thomas Reinheckel; Junjun Ni; Zhou Wu; Mark Kindy; Christoph Peters; Vivian Hook
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Cathepsin B Relocalization in Late Membrane Disrupted Neurons Following Diffuse Brain Injury in Rats.

Authors:  Martina L Hernandez; Michael Marone; Karen M Gorse; Audrey D Lafrenaye
Journal:  ASN Neuro       Date:  2022 Jan-Dec       Impact factor: 5.200

4.  Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B.

Authors:  Michael C Yoon; Mitchell P Christy; Von V Phan; William H Gerwick; Gregory Hook; Anthony J O'Donoghue; Vivian Hook
Journal:  Biochemistry       Date:  2022-02-04       Impact factor: 3.321

5.  Single Molecule Assay for Ultrasensitive Detection of Cathepsin B in Human Blood.

Authors:  Bharani Thangavelu; Angela M Boutté
Journal:  ACS Omega       Date:  2021-03-31

6.  Blood-Based Brain and Global Biomarker Changes after Combined Hypoxemia and Hemorrhagic Shock in a Rat Model of Penetrating Ballistic-Like Brain Injury.

Authors:  Xue Li; Kevin Pierre; Zhihui Yang; Lynn Nguyen; Gabrielle Johnson; Juliana Venetucci; Isabel Torres; Brandon Lucke-Wold; Yuan Shi; Angela Boutte; Deborah Shear; Lai Yee Leung; Kevin K W Wang
Journal:  Neurotrauma Rep       Date:  2021-08-12

Review 7.  Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders.

Authors:  Vivian Hook; Michael Yoon; Charles Mosier; Gen Ito; Sonia Podvin; Brian P Head; Robert Rissman; Anthony J O'Donoghue; Gregory Hook
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-04-17       Impact factor: 3.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.